ZFIN ID: ZDB-FIG-200401-3
Lin et al., 2019 - Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers   11(6) Full text @ Cancers
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Anatomical Term:
Stage: Adult
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Adult

Fig. 7

The treatment of 419S1 and 420S1 blocked HCC formation in Tg(fabp10a:HBx,src, p53) transgenic zebrafish. (AC) Dot-plot of relative expression fold of cell-cycle-related genes ccne1cdk1, and cdk2 after 419S1 and 420S1 oral gavage for one month in Tg(fabp10a:HBx,src, p53) compared to control fish. DMSO-treated Tg(fabp10a:HBx,src, p53) fish exhibited high levels of ccne1cdk1, and cdk2 expression compared to control fish. DMSO- (black circle), 419S1- (red square), and 420S1 (blue triangle)-treated Tg(fabp10a:HBx,src, p53) fish showed significantly decreased ccne1cdk1, and cdk2 expression compared to DMSO. (D) Dot-plot of relative expression fold of immunoreactive score (IRS), which was obtained by multiplying the intensity grade by the percentage rating from PCNA IHC stain. (E) Percentage of fish with various histopathological features revealed by H&E stain after different drug treatments for one month. Red indicates HCC, orange denotes dysplasia, yellow represents hyperplasia, green denotes steatosis, and grey is normal hepatocyte. (F) Representative images of H&E stain (400 ×) and PCNA IHC staining after 419S1 and 420S1 oral gavage for one month in Tg(fabp10a:HBx,src, p53) compared to DMSO control. Scare bar: 100 μm. *: 0.01 < p ≤ 0.05; **: 0.001 < p ≤ 0.01; ****: p ≤ 0.0001

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
ccne1 tp53zdf1/zdf1; nn1002Tg; nn1004Tg increased food availability Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg; nn1004Tg chemical treatment by gavage: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, increased food availability Adult liver RTPCR
cdk1 tp53zdf1/zdf1; nn1002Tg; nn1004Tg increased food availability Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg; nn1004Tg chemical treatment by gavage: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, increased food availability Adult liver RTPCR
cdk2 tp53zdf1/zdf1; nn1002Tg; nn1004Tg increased food availability Adult liver RTPCR
tp53zdf1/zdf1; nn1002Tg; nn1004Tg chemical treatment by gavage: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, increased food availability Adult liver RTPCR
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
tp53zdf1/zdf1; nn1002Tg; nn1004Tg increased food availability Adult liver ccne1 expression increased amount, abnormal
Adult liver cdk1 expression increased amount, abnormal
Adult liver cdk2 expression increased amount, abnormal
Adult liver cell population proliferation increased occurrence, abnormal
Adult liver dysplastic, exacerbated
Adult liver hepatocellular carcinoma increased amount, exacerbated
Adult liver hyperplastic, exacerbated
Adult liver lipid increased amount, exacerbated
tp53zdf1/zdf1; nn1002Tg; nn1004Tg chemical treatment by gavage: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, increased food availability Adult liver ccne1 expression amount, ameliorated
Adult liver cdk1 expression amount, ameliorated
Adult liver cdk2 expression amount, ameliorated
Adult liver cell population proliferation occurrence, ameliorated
Adult liver hepatocellular carcinoma amount, ameliorated
Adult liver lipid amount, ameliorated
Adult liver structure, ameliorated
Acknowledgments:
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancers